In vitro cytotoxicity, in vivo pharmacokinetic studies and tissue distribution studies of multifunctional citric acid dendrimers using the drug Cytarabine
Keywords:
Citric acid, Cytarabine, Dendrimers, Leukemia, PEGylation, TumorAbstract
Dendrimers are considered the emerging polymeric architectures, known for their well defined molecular-weight, polydispersity, uniformity and high-surface functionality. These nano-architectures are capable of encapsulating low-high molecular-weight drug moieties in their interior or exterior through covalent bonding and host-guest interactions. Further, large surface volume made researchers to implicate dendrimers in biomedical and therapeutic applications. Regardless of the massive applications, sometimes its use is limited because of the cytotoxicity produced. Considering this, the present research is focused on the synthesis and PEGylation of citric acid dendrimers. PEGylation is an act of conjugating polyethylene glycol to dendrimers that completely eliminates the toxicity issues associated with dendrimers and render them biocompatible. Cytarabine was loaded in the dendritic architecture to target specifically the tumor cells. Dendrimers are made tumor specific by incorporating certain agents that get cleaved in tumor environment. Synthesized dendrimers were studied for its effect on acute cytotoxicity, tissue-distributions and pharmacokinetic parameters.
References
. Malik A, Chaudhary S, Garg G, Tomar A. Dendrimers: A Tool for Drug Delivery. Adv Biol Res. 2012;6:165-169.
. Athar M, Das AM. Therapeutic nanoparticles: State of the art of Nanomedicine. Adv Mater Rev. 2014;1:25-37.
. Patel HN, Patel PM. Dendrimer Applications- A Review. Int J Pharm Biosci. 2013;4:454-463.
. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers. Int J Nanomed. 2009;4:1-7.
. Baker JR. Dendrimer-Based Nanoparticles for Cancer Therapy. Haematol Am Soc Hematol. 2009:708-719.
. Madaan K, Kumar S, Poonja N, Lather V, Pandita D. Dendrimers in drug delivery and Targeting: Drug- Dendrimer interactions and toxicity issues. J Pharm BioAll Sci. 2014;6:139-150.
. Namazi H, Motamedi S, Namvari M. Synthesis of New Functionalized Citric Acid-Based Dendrimers as Nanocarrier agents for Drug delivery. Bioimpacts. 2011;1:63-69.
. Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, Hanifehpour Y, Koshki KN, Pashaei-Asl R. Dendrimers: Synthesis, applications and properties. Nanoscale Res Lett, 2014;9:247.
. Patel RM, Gajjar DG, Patel HN, Patel PM. Dendrimers – An Overview. Int J Chem Sci Appl. 2014;5:94-106.
. Kumar BP, Chandiran IS, Bhavya B, Sravanthi U, Sindhuri M. Dendrimer: A Complete Drug Carrier. Int J Pharm Rev Res. 2011;1:25-39.
. Namazi H, Adeli M. Dendrimers of citric acid and poly(ethylene glycol) as the new drug- delivery agents, Biomaterials. 2005;26:1175-1183.
. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for Cancer treatment. Adv Drug Deliv Rev. 2008; 60:1037-1055.
. Rao BN, Viswanath V, Purushothaman M, Vaishnavi VP. Synthesis and Formulation of new Functionalized Citric Acid based Dendrimers for Drug Delivery using an Anti Bacterial agent World. J Pharm Res. 2015;4:1054-1062.
. Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: An overview. Asian J Pharm Sci. 2016;11:337–348.
. Reddy MS, Tejaswi Y, Kalyan AV, Sravya R, Namrath M. Novel Drug Delivery of Minocycline aganist Bacteria by using a Polymer Citric Acid macro molecule. Indian J Res Pharm Biotech. 2014;2:1161–1166.
. Oddone N, Lecot N, Fernandez M, Haralambides AR, Cabra P, Cerecetto H, BenechBC. In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer. J Nanobiotech. 2016;14.
. Hemmer R, Hall A, Spaulding R, Rossow B, Hester M, Caroway M, Haskamp A, Wall S, Bullen HA, Morris C, Haik KL. Analysis of biotinylated generation 4 poly(amidoamine) (PAMAM) dendrimer distribution in the rat brain and toxicity in a cellular model of the blood-brain barrier, Molecules. 2013;18:11537-11552.
